AstraZeneca (GB:AZN) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca’s drug Fasenra has received FDA approval in the U.S. for treating eosinophilic granulomatosis with polyangiitis (EGPA), a rare, life-threatening immune-mediated vasculitis. Grounded in the successful MANDARA trial, Fasenra showed that nearly 60% of patients achieved remission, and 41% could cease oral corticosteroid use, offering a significant new treatment option for the approximately 15,000 U.S. patients with this rare disease.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.